R. A. Claro

Path to Market Approval: Regulatory Perspective of ADC Nonclinical Safety Assessments

M. Ricci, R. A. Claro, Natalie E. Simpson, 2016 .

FDA review summary of patient-reported outcome results for ibrutinib in the treatment of chronic graft versus host disease

B. King-Kallimanis, A. Farrell, P. Kluetz, 2020, Quality of Life Research.

Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.

J. Gribben, F. Cavalli, T. Habermann, 2018, The Lancet. Haematology.

FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma

Amy McKee, R. Pazdur, B. George, 2018, Clinical Cancer Research.